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Chondrocyte activity is increased in
psoriatic arthritis and axial spondyloarthritis
Natasja Stæhr Gudmann1*, Heidi Lausten Munk2, Anne Friesgaard Christensen3, Leif Ejstrup4, Grith Lykke Sørensen5,
Anne Gitte Loft3,6, Morten Asser Karsdal1, Anne-Christine Bay-Jensen1, Yi He1, Anne Sofie Siebuhr1 and Peter Junker2
Abstract
Background: Psoriatic arthritis (PsA) and axial spondyloarthritis (axSpA) are chronic inflammatory rheumatic
diseases with complex origins. Both are characterized by altered extracellular matrix remodeling in joints and
entheses that results in destructive and osteochondral proliferative lesions. There is a need for biomarkers reflecting
core disease pathways for diagnosis and disease mapping. Pro-C2 reflects mature cartilage collagen type IIB
formation, while C-Col10 represents turnover of type X collagen, which is exclusively expressed by hypertrophic
chondrocytes. The objectives of this study were to study cartilage metabolism in axSpA and PsA by assessing
Pro-C2 and C-Col10 and to evaluate their diagnostic utility against a healthy reference population.
Methods: Patients with PsA (n = 101) or axSpA (n = 110) were recruited consecutively from three rheumatology
outpatient clinics. Demographic and clinical disease measures were recorded. Pro-C2 and C-Col10 were quantified
in serum by using newly developed and specific competitive enzyme-linked immunosorbent assays based on
monoclonal antibodies. One-way analysis of variance and Tukey’s multiple comparison tests were performed on
log-transformed data. ROC curve analysis was carried out to evaluate their discriminative power.
Results: Pro-C2 levels in serum were significantly increased in both axSpA (median concentration 1.11 ng/ml, 0.67–1.
64) and PsA (median concentration 1.03 ng/ml, 0.53–1.47) compared with healthy controls (median concentration 0.
30 ng/ml, 0.16–0.41) (p < 0.0001). Pro-C2 did not differ according to treatment. C-Col10 was slightly but equally
elevated in the PsA and axSpA groups vs. the control group, but it was significantly lower in patients with axSpA
undergoing tumor necrosis factor-α inhibitor (TNFi) treatment. ROC curve analysis revealed AUCs of 0.85 (95 %
CI 0.79–0.89) for axSpA and 0.81 (95 % CI 0.75–0.86) for PsA.
Conclusions: These findings indicate that cartilage collagen metabolism was enhanced in the axSpA and PsA
groups compared with the healthy control group. The lower C-Col10 level in patients with axSpA undergoing
TNFi treatment may reflect that hypertrophic chondrocytes in axSpA are targeted by TNFi. ROC curve analysis
showed a diagnostic potential for Pro-C2 in axSpA and PsA.
Keywords: Spondyloarthritis, Psoriatic arthritis, Type II collagen, Type X collagen, Pro-C2, C-Col10
Background
The spondyloarthropathies (SpAs) are chronic inflam-
matory rheumatic diseases with shared as well as dis-
tinctive genetic and clinical features. Joint structural
elements and entheses of the axial and peripheral
skeleton are principal targets of the diseases [1],
which are occasionally also manifested at extraskeletal
sites (e.g., anterior uveitis, aortic valvulopathy, and
apical lung fibrosis) [1, 2]. Both genetic and environ-
mental factors are implicated in the disease course
[3–5], and human leukocyte antigen (HLA)-B27 is
overrepresented, occurring in up to 83 % of patients
with axial involvement [6].
Disease presentation and progression in SpAs differ
between individuals. If left untreated, many patients will
experience spinal and peripheral joint deformities due to
altered bone and cartilage turnover. Osteochondral pro-
liferative lesions are hallmarks of axial and entheseal
* Correspondence: nsg@nordicbioscience.com
1Nordic Bioscience Biomarkers and Research, Herlev Hovedgade 207, Herlev
2730, Denmark
Full list of author information is available at the end of the article
© 2016 The Author(s). Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Gudmann et al. Arthritis Research & Therapy  (2016) 18:141 
DOI 10.1186/s13075-016-1040-z
involvement [7]. Current treatments include nonsteroi-
dal anti-inflammatory drugs, methotrexate, and bio-
logical agents such as tumor necrosis factor-α inhibitors
(TNFi) [8]. Early intervention is recommended to pre-
vent or slow the progression rate. However, early diag-
nosis is challenging because of a lack of pathognomonic
features and/or laboratory tests, and the average
diagnostic delay has been reported to be approximately
8–11 years [7]. In psoriatic arthritis (PsA), early diagno-
sis has been shown to significantly decrease morbidity
and increase quality of life [9]. Thus, interest in develop-
ing sensitive and specific tools for diagnostic and prog-
nostic purposes is increasing. The utility of several
cartilage and bone biochemical markers has been
assessed, particularly in osteoarthritis and rheumatoid
arthritis, and also, although less intensively, in axial
spondyloarthritis (axSpA) and PsA [10]. Thus, markers
of cartilage formation (type II collagen [CII] [11]) and
degradation (collagen type II cleavage [C2C] [11] and C-
terminal telopeptide of type II collagen [CTX-II] [12])
have been shown to be elevated in axSpA and PsA. Simi-
lar findings have been reported recently with use of the
regenerative collagen type IIA N-terminal propeptide
(PIIANP) and matrix metalloproteinase-generated type
II collagen degradation fragment (C2M) [13]. The Pro-
C2 assay is the first laboratory tool for specific measure-
ment of the N-terminal propeptide of the procollagen
IIB splice variant (PIIBNP), which is the most prevalent
collagen species in healthy adult cartilage. By contrast,
previous candidate markers for type II collagen forma-
tion either do not segregate other variants such as CII
[11], NPII [14], and PIINP [15] or are specific for
PIIANP, which is expressed mainly during embryogen-
esis, fracture healing, and cartilage regeneration [16–18].
Additionally, C-Col10 is, to our knowledge, the first
marker available for the assessment of type X collagen
turnover, and so far it has been applied only to patients
with osteoarthritis [19].
On the basis of these observations, we hypothesized
that remodeling of mature collagen IIB and collagen X, a
minor collagen species that is produced only by hyper-
trophic chondrocytes, is increased in axSpA and PsA.
The aims of this study were (1) to study cartilage colla-
gen metabolism in further detail using novel molecular
markers for the synthesis and turnover of mature colla-
gen IIB (Pro-C2) [20] and collagen X (C-Col10) [19] in
well-characterized cohorts of patients with axSpA and
PsA, and (2) to assess their diagnostic utility in compari-
son with healthy control subjects.
Methods
Study populations
Patients from three rheumatology centers in Southern
Denmark were recruited from November 2011 through
February 2014 (33–120 patients per center). The in-
clusion criteria and patient characteristics have previ-
ously been published [13]. In short, 110 patients with
axSpA classified according to the Assessment of
SpondyloArthritis international Society (ASAS) criteria
[21, 22] and 101 patients with PsA fulfilling the
Classification of Psoriatic Arthritis (CASPAR) criteria
[23] were enrolled in the study. Sixteen of the pa-
tients fulfilled both the CASPAR and the ASAS cri-
teria, and these patients were labeled as having PsA
in this study. Exclusion criteria were age <18 years and
age >75 years, past or present malignancy (except nonma-
lignant skin cancer), congestive cardiac disease (New
York Heart Association classes III and IV), pulmonary
disease (dyspnea at rest), serum creatinine above the
upper limit of normal, serum concentration of alanine
aminotransferase more than two times the upper limit
of normal, infection with hepatitis B or hepatitis C
virus, and/or presence of other chronic inflammatory
diseases. The patient characteristics recorded included
sex, body mass index (BMI), age, smoking habit, alcohol
consumption, treatment, and HLA-B27 status. Disease
measures recorded included 68 swollen joint count
(68SJC), 68 tender joint count (68TJC), Spondyloarthritis
Research Consortium of Canada enthesitis index, Health
Assessment Questionnaire (HAQ), visual analogue scale
(VAS; patient pain, patient global, patient fatigue, and
physician global scores on a 0–10 scale), Bath Ankylosing
Spondylitis Disease Activity Index (BASDAI), Disease
Activity Score in 28 joints (DAS28), and Ankylosing
Spondylitis Disease Activity Score (ASDAS). X-rays or
magnetic resonance imaging (MRI) scans of sacroiliac
joints of patients with axSpA and of patients with PsA
with axial involvement were available when the disease
was diagnosed, but they were not repeated in this study.
Twelve patients with axSpA had ankylosis of the sacroiliac
joints visualized on x-rays or MRI scans. Demographic
data and disease parameters are summarized in Table 1.
One hundred eighteen blood donors aged 20–65 years
served as healthy control subjects. Blood samples were
collected in plain tubes from subjects in nonfasting state.
The samples were allowed to clot for 30–120 minutes and
then centrifuged for 12 minutes at 2200 rpm. Serum sam-
ples were frozen at −80 °C until used for analysis.
Biomarker measurements
The Pro-C2 competitive enzyme-linked immunosorbent
assay (ELISA) has been described previously by
Gudmann et al. [20]. In short, 96-well streptavidin-
coated plates (Roche Diagnostics, Risch-Rotkreuz,
Switzerland) were coated with the biotinylated synthetic
peptide Bio-QDVRQPG, dissolved in assay buffer
(100 mM PBS, 1 % bovine serum albumin, 0.1 % Tween-
20, 0.36 % 5-bromo-5-nitro-1,3-dioxane [Bronidox; BASF,
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Florham Park, NJ, USA], 8 % NaCl, pH 7.4), and incu-
bated for 30 minutes at 20 °C. The peptide calibrator or
sample in a quantity of 20 μl was added to appropriate
wells, followed by 100 μl of antibody of the NB443-3-2-1
clone. The plates were then incubated for 2 h. Afterward,
100 μl of EnVision (Dako, Glostrup, Denmark) was added,
and the plate was incubated for 1 h. Finally, 100 μl of
3,3′,5,5′-tetramethylbenzidine (TMB) (Kem-En-Tec Nor-
dic, Taastrup, Denmark) was added, and the plate was
incubated for 15 minutes at 20 °C in the dark. The
C-Col10 ELISA method has been described in detail
previously by He et al. [19]. Measurements were per-
formed as follows: 100 μl of biotinylated peptide of
the sequence SFSGFLVAPM was added to plates pre-
coated with streptavidin (Roche Diagnostics) and incu-
bated at 20 °C for 30 minutes. Standard or patient samples
in a quantity of 20 μl was then added to the appropriate
wells together with 100 μl of peroxidase-labeled antibody
NB509-11G8 and incubated at 4 °C overnight with shak-
ing. Afterward, 100 μl of TMB was added to each well of
the plates and incubated in the dark at 20 °C for 15 mi-
nutes. All samples were measured in duplicate, and incu-
bation steps included shaking at 300 rpm for both assays.
After each incubation except the last one in which TMB
was added, the plates were washed five times in washing
buffer (20 mM Tris, 50 mM NaCl, pH 7.2). The TMB re-
action was stopped by adding 100 μl of stopping solution
(1 % H2SO4) and measured at 450 nm with 650 nm as the
reference.
Statistics
All analyses were performed using MedCalc statistical
software version 14.8.1 (2014 release; MedCalc Software
bvba, Ostend, Belgium). Means were calculated for vari-
ables with a normal distribution, and medians were cal-
culated for variables that were not normally distributed.
Biomarker levels and parameters that did not meet the
criteria for normal distribution were log-transformed.
Normally distributed variables were compared using t
tests, and one-way analysis of variance followed by
Tukey’s multiple comparisons test were applied for
intergroup comparisons. Correlation analyses were per-
formed by using Pearson’s test. A p value ≤0.05 was consid-
ered statically significant. The discriminative power of the
serum markers between healthy and diseased states was
calculated by using ROC and expressed by the AUC. The
Youden index was applied to determine the optimum sensi-
tivity and specificity and the corresponding cutoff values.
Results
Patient demographics
Patient demographics and disease characteristics are
presented in Table 1. Male sex was more common in
both axSpA (72 %) and PsA (59 %) than in the con-
trol group (50 %). The clinical parameters are listed
for patients, but they were not available for healthy
blood donors.
Cartilage turnover is increased in axSpA and PsA
Pro-C2 was significantly increased in the axSpA and PsA
groups compared with the healthy control group
(Fig. 1a). Similarly, C-Col10 was significantly elevated in
patients with PsA compared with healthy control sub-
jects, and the same trend was observed in patients with
axSpA (Fig. 1b). Of note, in patients with axSpA naïve to
TNFi treatment (n = 34), C-Col10 was significantly
higher in patients with axSpA than in TNFi-treated pa-
tients and healthy control subjects (p = 0.008). There
was no significant difference in Pro-C2 or C-Col10 be-
tween the axSpA and PsA groups.
Pro-C2 associations
Pro-C2 correlated with ASDAS in the patients with
axSpA naïve to disease-modifying antirheumatic drugs
Table 1 Patient characteristics, disease measures, and serum
levels of Pro-C2 and C-Col10
axSpA (n = 110) PsA (n = 101) Control
Male sex, % 72 % 59 %
Age, years 36.6 (35.3–38.0) 37.0 (35.6–38.5)
BMI, kg/m2 25.5 (24.8–26.3) 27.4 (26.2–28.5)
Smoker, % 36 % 35 %
HLA-B27 positive, % 87 % 20 %
Disease duration,
years
6.4 (5.4–7.5) 6.7 (5.6–7.8)
VAS
Patient global 34 (29–39) 39 (34–45)
Patient pain 32 (27–37) 32 (27–37)
Patient fatigue 40 (34–45) 43 (37–49)
Physician global 4 [1–16] 3 [1–14]
BASDAI 31 (26–35) 36 (31–41)
BASFI 23 (19–27) 27 (22–32)
BASMI 10 [0–20] 10 [0–10]
ASDAS (CRP) 2.0 (1.8–2.3) 2.1 (1.9–2.4)
Swollen joints, % 9 % 38 %
hs-CRP, mg/dl 3 [1–7] 3 [1–9]
Pro-C2, ng/ml 1.11 [0.67-1.64] 1.03 [0.53-1.47] 0.30 [0.16-0.41]
Col-X, ng/ml 0.45 [0.28-0.67] 0.42 [0.31-0.72] 0.33 [0.31-0.45]
Abbreviations: ASDAS Ankylosing Spondylitis Disease Activity Score, axSpA axial
spondyloarthritis, BASDAI Bath Ankylosing Spondylitis Disease Activity Index,
BASFI Bath Ankylosing Spondylitis Functional Index, BASMI Bath Ankylosing
Spondylitis Metrology Index, BMI body mass index, HLA-B27 human leukocyte
antigen B27, hs-CRP high-sensitivity C-reactive protein, PsA psoriatic arthritis,
VAS visual analogue scale
Data are presented as mean (95 % CI) for variables with a normal distribution
and as median [25th–75th percentile range] for variables that were not
normally distributed
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(DMARDs). In treatment-naïve patients with PsA Pro-C2,
there was a borderline correlation with age, BMI, and
disease duration. Patients with axSpA currently being
treated with synthetic and/or biological DMARDs had
a significant correlation between Pro-C2 and HAQ
and Bath Ankylosing Spondylitis Functional Index
(BASFI). HAQ and Pro-C2 were also significantly
correlated in currently treated patients with PsA
(Table 2).
HLA-B27-positive patients with axSpA had signifi-
cantly lower Pro-C2 levels than HLA-B27-negative pa-
tients (p = 0.026) (Fig. 2). In contrast, we found no
statistically significant differences in Pro-C2 levels
when we compared subjects according to smoking
status (p = 0.51), male vs. female sex (p = 0.46),
current treatment (neither biologics [p = 0.50] nor
synthetic DMARDs [p = 0.15]), SJC28 (p = 0.63), or TJC28
(p = 0.28). We observed no significant differences in
Fig. 1 a Pro-C2 was significantly increased in the axial spondyloarthritis (axSpA) and psoriatic arthritis (PsA) groups compared with the healthy
control group. b C-Col 10 concentrations were slightly but significantly higher in the PsA group compared with the healthy control group. Error
bars are shown as SEM. One-way analysis of variance was performed for intergroup comparisons. *p < 0.05, ****p < 0.0001
Table 2 Pearson correlations between Pro-C2 levels in axial spondyloarthritis and psoriatic arthritis and clinical parameters
axSpA PsA
Total
(n = 110)
Treatment-naïve
(n = 34)
Currently treated,
total (n = 63)
Previously
treated (n = 13)
Total
(n = 101)
Treatment-naïve
(n = 13)
Currently treated,
total (n = 76)
Previously
treated (n = 12)
Age ns ns ns ns ns r = −0.55 ns ns
p = −0.051
BMI ns ns ns ns ns r = 0.60 ns ns
p = 0.032
Disease duration ns ns ns r = 0.54 ns r = 0.55 ns ns
p = 0.030 p = 0.052
ASDAS ns r = 0.45 ns ns ns ns ns ns
p = 0.008
HAQ ns ns r = 0.47 ns r = −0.34 ns r = −0.35 ns
p = 0.010 p = 0.004 p = 0.008
Sex ns ns ns ns ns ns ns ns
BASDAI ns ns ns ns ns ns ns ns
BASFI ns ns r = −0.30 ns ns ns ns ns
p = 0.008
SJC68 ns ns ns ns ns ns ns r = −0.92
p = 0.0001
TJC68 ns ns ns ns ns ns ns r = −0.89
p = 0.0003
Abbreviations: ASDAS Ankylosing Spondylitis Disease Activity Score, axSpA axial spondyloarthritis, BASDAI Bath Ankylosing Spondylitis Disease Activity Index, BASFI
Bath Ankylosing Spondylitis Functional Index, BASMI Bath Ankylosing Spondylitis Metrology Index, BMI body mass index, HAQ Health Assessment Questionnaire, ns
not significant, SJC68 68 swollen joint count, TJC68 68 tender joint count
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Pro-C2 when we compared subjects according to
HLA-B27 status in PsA (p = 0.18), and this applied to
other clinical parameters as well (data not shown).
C-Col10 associations
In patients with axSpA who were naïve to treatment, a
weak correlation was found between C-Col10 and disease
duration and SJC68. In patients with axSpA currently re-
ceiving treatment (synthetic and/or biologic DMARDs), a
correlation was found between sex and C-Col10. No cor-
relation was found between type X collagen in serum and
disease parameters in patients with PsA (Table 3).
C-Col10 levels were significantly lower in patients with
axSpA who received or had previously received DMARD
biologics (p = 0.019) than in those who did not, whereas
treatment with a synthetic DMARD did not affect C-
Col10 concentration (p = 0.96) (Fig. 3). This pattern did
not apply to patients with PsA (p = 0.34). C-Col10 did
not associate with sex, HLA-B27, SJC28, TJC28, or
disease state as assessed using either DAS28, ASDAS,
BASDAI, or BASFI in patients with axSpA or PsA (data
not shown).
Discriminative power of Pro-C2 and C-Col10
The discriminating power between the healthy control,
axSpA, and PsA groups was assessed by ROC analysis
(Fig. 4). The AUCs of the healthy control group vs.
disease groups were, for both biomarkers, approximately
Fig. 2 Pro-C2 was significantly lower in patients with axial spondyloarthritis (axSpA) who were positive for the human leukocyte antigen (HLA)-
B27 gene compared with the HLA-B27-negative patients. In patients with psoriatic arthritis (PsA), Pro-C2 did not differ significantly according to
HLA-B27 status (p=0.31). Error bars are shown as SEM. Student’s t test was applied to compare the two groups. *p < 0.05. ns not significant
Table 3 Pearson correlations between C-Col10 levels in axial spondyloarthritis and psoriatic arthritis and clinical parameters
axSpA PsA
Total
(n = 110)
Treatment-naïve
(n = 34)
Currently treated
(n = 63)
Previously treated
(n = 13)
Total
(n = 101)
Treatment-naïve
(n = 13)
Currently treated
(n = 76)
Previously treated
(n = 12)
Age ns ns ns ns ns ns ns ns
BMI ns ns ns ns ns ns ns ns
Disease
duration
ns r = −0.38 ns ns ns ns ns ns
p = 0.027
ASDAS ns ns ns ns ns ns ns ns
Alcohol
consumption
ns ns ns r = −0.60 ns ns ns ns
p = 0.022
HAQ ns ns ns ns ns ns ns ns
Sex ns ns r = 0.30 ns ns ns ns ns
p = 0.021
BASDAI ns ns ns ns ns ns ns ns
SJC68 ns r = −0.36 ns ns ns ns ns ns
p = −0.037
TJC68 r = −0.20 ns ns ns ns ns ns r = −0.73
p = 0.043 p = 0.011
Abbreviations: ASDAS Ankylosing Spondylitis Disease Activity Score, axSpA axial spondyloarthritis, BASDAI Bath Ankylosing Spondylitis Disease Activity Index, BMI
body mass index, HAQ Health Assessment Questionnaire, ns not significant, PsA psoriatic arthritis, SJC68 68 swollen joint count, TJC68 68 tender joint count
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the same for the two diseases. For Pro-C2, the
healthy control group vs. the axSpA group had an
AUC of 0.85 (95 % CI 0.79–0.89); for the healthy
control group vs. the PsA group, the AUC was 0.81
(95 % CI 0.75–0.86) (see Table 4). For C-Col10, the
AUC of the healthy control group vs. the disease
groups was lower than that for Pro-C2 but approxi-
mately the same in the two disease groups. The AUC
for the healthy control group vs. the axSpA group
was 0.58 (95 % CI 0.51–0.65), and for the healthy
control group vs. the PsA group it was 0.61 (95 % CI
0.54–0.67) (Table 4).
Discussion
Structural elements in joints and entheses are major dis-
ease targets in axSpA [24] and PsA [25]. Therefore, in
the present study, we measured two recently developed
cartilage biochemical markers—C-Col10 and Pro-C2—to
study chondrocyte differentiation and mature cartilage
collagen IIB formation in axSpA and PsA.
Pro-C2 concentrations were significantly elevated in
both the axSpA and PsA groups compared with levels in
control subjects. In addition, C-Col10 levels were slightly
higher in both disease subsets than the levels in control
subjects, although they reached statistical significance
only in the PsA group. Pro-C2 correlated with ASDAS
in untreated patients with axSpA and with HAQ and
BASFI in TNFi-treated patients with axSpA. C-Col10
was weakly associated with SJC68. While Pro-C2 was
not influenced by TNFi treatment, C-Col10 was lower in
patients with axSpA currently or previously receiving bi-
ologics than in patients naïve to TNFi treatment. Good
discrimination for Pro-C2 was seen for patients with
axSpA and patients with PsA vs. healthy subjects.
Fig. 3 C-Col10 was significantly higher in patients with axial spondyloarthritis (axSpA) naïve to biological treatment than in those currently or
formerly treated with biologic DMARDs. The same trend was observed in patients with psoriatic arthritis (PsA), though it did not reach statistical
significance. Error bars are shown as SEM. Student’s t test was applied to compare the two groups. *p < 0.05. ns not significant
Fig. 4 ROC analysis of (a) Pro-C2 in the axial spondyloarthritis (axSpA)
group vs. the healthy control group, (b) Pro-C2 in the psoriatic arthritis
(PsA) group vs. the healthy control group, (c) C-Col10 levels in the
axSpA group vs. the healthy control group, and (d) C-Col10 in the PsA
group vs. the healthy control group
Table 4 ROC analysis of ability of Pro-C2 and C-Col10 to
differentiate between healthy control, psoriatic arthritis, and
axial spondyloarthritis groups
AUC (95 % CI) Youden
index
Sensitivity Specificity
Pro-C2
Healthy vs. axSpA 0.85 (0.79–0.89) 0.58 87.9 70.6
Healthy vs. PsA 0.81 (0.75–0.86) 0.51 92.7 58.8
axSpA vs. PsA 0.54 (0.47–0.61) 0.13 17.43 95.2
C-Col10
Healthy vs. axSpA 0.58 (0.51–0.65) 0.18 67.0 51.4
Healthy vs. PsA 0.61 (0.54–0.67) 0.21 69.7 51.4
axSpA vs. PsA 0.52 (0.45–0.59) 0.11 94.5 16.8
axSpA axial spondyloarthritis, PsA psoriatic arthritis
Gudmann et al. Arthritis Research & Therapy  (2016) 18:141 Page 6 of 9
Guidelines for treatment of axSpA and PsA rely
mainly on clinical assessment of disease activity and pro-
gression [26, 27]. Thus, biologically plausible biomarkers
may provide additional information regarding diagnosis
and assessment of disease activity, and they may also
help to guide treatment [28, 29]. We previously reported
that type II collagen seromarkers differ between axSpA
and PsA [13]. However, this report was based on the
marker of mature collagen II (C2M) [30] and a marker
of regenerative collagen II formation (PIIANP) [31]. In
the present study, we wanted to extend these previous
observations using Pro-C2, a marker of mature collagen
synthesis, and C-Col10, a fragment of collagen X. Thus,
Pro-C2 and PIIANP reflect the synthesis of two different
splice variants of procollagen II. Type IIA procollagen is
expressed mainly during embryogenesis [32] and has
been found to be reexpressed in osteoarthritis [16]. The
PIIANP splice variant is considered to represent a dedif-
ferentiated version of type II collagen [31]. By contrast,
collagen type IIB N-terminal propeptide (PIIBNP) is
considered to be the only procollagen expressed during
type II collagen formation in healthy adult cartilage [17].
Pro-C2 is specific for evaluation of the PIIBNP splice
variant [20]. This allows for discrimination between
structural type IIB vs. regenerative cartilage type IIA
formation in healthy and diseased states. The present
study shows that mature collagen II synthesis as
reflected by Pro-C2 is increased in both axSpA and PsA,
while our previous study showed that PIIANP was in-
creased only in currently untreated patients with PsA
and in treatment-naïve patients with axSpA compared
with control subjects [13]. Notably, Pro-C2 was not af-
fected by DMARD treatment in axSpA or PsA, while
PIIANP was lower in treated than in untreated patients,
probably reflecting suppression of a cartilage pathogenic
pathway [13]. The increased on-treatment Pro-C2 levels
likely reflect that mature cartilage collagen IIB synthesis
is maintained despite drug treatment. The increased
Pro-C2 levels correlated significantly with physical func-
tion scores but not with joint counts, which may reflect
a mature chondrocyte response to altered mechanical in-
fluences on cartilage elicited by synovial and entheseal
pathologies [33]. The lower Pro-C2 concentration in
HLA-B27-positive patients with axSpA than in HLA-
B27-negative patients suggests that the HLA-B27 gene is
implicated in the regulation of type II collagen expres-
sion, as recently proposed for procollagen IIA in axSpA
[13]. Our findings add to those described by Pedersen et
al., who reported that the urinary excretion of CTX-II, a
marker of collagen II degradation, was increased in
axSpA but decreased during TNFi treatment [12]. Thus,
the current increased Pro-C2 level may reflect an ana-
bolic chondrocyte response to counterbalance increased
collagen type II degradation in active disease.
By analogy with osteoarthritis, we hypothesized that
C-Col10 levels would be increased in SpA as a marker
of syndesmophyte outgrowth similar to osteophyte for-
mation [21, 22, 34, 35]. Thus, C-Col10 was significantly
increased in patients with PsA as compared with control
subjects. The same trend was observed in axSpA, al-
though it did not reach statistical significance. However,
C-Col10 was significantly lower in patients with axSpA
treated with biologic DMARDs than in those naïve to
biological treatment, indicating that hypertrophic chon-
drocytes and collagen X expression are suppressed by
TNFi. This response contrasts with Pro-C2, indicating
that household collagen II formation is left unaffected by
TNF-α inhibition, while potential cartilage osteochon-
dral precursor collagen is suppressed. This observation
and the association between C-Col10 and SJC lend sup-
port to the concept that chondrocyte hypertrophy and
increased expression of type X collagen are implicated in
the axSpA disease pathway. However, in a recent study,
Bleil et al. [23] reported that chondrocyte hypertrophy
was not present in the facet joints of patients with
axSpA as assessed by immunohistochemistry. These
authors studied cartilage from patients with advanced
ankylosing spondylitis, in which the chondrocyte pheno-
type and distribution may be different from early active
disease and therefore may have a different type X colla-
gen expression profile. C-Col10 levels in osteoarthritis
(OA) have previously been studied in patients stratified
according to the Kellgren and Lawrence scoring system.
In that study, C-Col10 was significantly elevated in pa-
tients with intermediate structural OA changes vs. pa-
tients with severe or no abnormalities [19]. However, the
cartilage pathology of OA may differ from that of axSpA,
and the patient populations were not comparable in
terms of age, sex, or disease duration. Alternatively, the
increased release of type X collagen fragments may ori-
ginate from cartilage in areas other than the facet joints
in patients with axSpA. However, the risk of concurrent
osteoarthritis in the present patient populations is con-
sidered to be low because the median age was only
around 35 years.
Some limitations of the present study should be con-
sidered. The cross-sectional design provides an oppor-
tunity to evaluate the biochemical disease profile at a
specific time point, but it does not provide prognostic
information. No updated x-rays or MRI scans were avail-
able. Since this is the first report on Pro-C2 in a clinical
setting, it is uncertain how the present results compare
with findings in other joint diseases. The strengths of
this study are inclusion of two large and clinically well-
characterized patient populations with axSpA and PsA
and a large number of healthy control subjects. In
addition, this is the first time that Pro-C2 and C-Col10
have been applied to axSpA and PsA.
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Conclusions
This study presents a biochemical cartilage marker pro-
file in two disease subsets within the spondyloarthropa-
thy complex indicating the presence of hypertrophic and
enhanced chondrocyte activity, particularly in active
disease. While increased collagen IIB production was
unaffected by TNFi treatment, type X collagen of hyper-
trophic chondrocytes was suppressed by these agents.
This may indicate that the SpA-related type II collagen
response of normal chondrocytes is preserved, while the
collagen type X expression of cartilaginous and entheso-
pathic lesions is modified by TNFi. Prospective studies
are needed to validate this concept.
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